KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non-Current Liabilities: 2011-2025

Historic Other Non-Current Liabilities for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $11.4 million.

  • Supernus Pharmaceuticals' Other Non-Current Liabilities fell 75.63% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 75.63%. This contributed to the annual value of $47.3 million for FY2024, which is 11.43% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Other Non-Current Liabilities stood at $11.4 million, which was up 47.49% from $7.8 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $80.5 million during Q4 2021, with a 5-year trough of $7.8 million in Q2 2025.
  • Its 3-year average for Other Non-Current Liabilities is $41.7 million, with a median of $48.0 million in 2024.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Other Non-Current Liabilities spiked by 374.19% in 2021 and then slumped by 83.83% in 2025.
  • Supernus Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $80.5 million in 2021, then tumbled by 31.70% to $55.0 million in 2022, then fell by 2.76% to $53.5 million in 2023, then declined by 11.43% to $47.3 million in 2024, then slumped by 75.63% to $11.4 million in 2025.
  • Its Other Non-Current Liabilities was $11.4 million in Q3 2025, compared to $7.8 million in Q2 2025 and $30.0 million in Q1 2025.